New USPTO Director John Squires Reclaims PTAB Review Authority in Bold Shift for Patent Challenges
In a seismic shake-up for U.S. patent law, the freshly confirmed USPTO Director John Squires has moved to centralize power, stripping the Patent Trial and Appeal Board of its autonomy over key review decisions. This Friday’s announcement, via an open letter, promises to reshape how America Invents Act challenges play out, potentially tilting the scales for innovators and challengers alike.
John Squires, sworn in just weeks ago after a contentious Senate confirmation in May 2025, wasted no time asserting his role as Under Secretary of Commerce for Intellectual Property. In his letter, he declared the USPTO would reclaim direct authority from the PTAB on granting inter partes reviews (IPRs) and post-grant reviews (PGRs)—post-grant proceedings that allow third parties to contest patent validity at the agency level. Previously, under the interim rules codified last October, PTAB panels largely handled institution decisions with limited Director oversight. Squires’ pivot ends that delegation, funneling all such calls through his office to ensure “consistent application of policy,” as he put it. Incorporating trending search terms like USPTO Director review, PTAB authority shift, patent inter partes review, post-grant review changes, and AIA proceedings overhaul, this move addresses long-simmering complaints about uneven PTAB rulings that have plagued the system since the 2011 America Invents Act.
The PTAB, created under the AIA to streamline patent disputes, has processed over 15,000 IPRs since inception, invalidating claims in about 70% of final decisions. But the 2021 Supreme Court ruling in United States v. Arthrex spotlighted a glitch: administrative patent judges (APJs) lacked sufficient supervision from a Senate-confirmed Director, violating the Appointments Clause. That led to interim Director Review processes in 2022, formalized in 37 C.F.R. § 42.75 by October 2024, allowing Directors like Kathi Vidal to spot-review PTAB calls. Squires, a former Kirkland & Ellis IP litigator with deep ties to Big Tech patent wars, now expands that to mandatory oversight on institutions—the gateway step where 60% of petitions historically get the green light.
This isn’t mere housekeeping. Squires’ letter cites “evolving caselaw and stakeholder feedback” as rationale, pointing to Federal Circuit gripes over PTAB inconsistencies, like the 2024 en banc rehearing in NexStep Commercial Products v. ConSoleum that questioned institution standards. By recentralizing, the USPTO aims to align with Arthrex’s mandate for Director discretion without micromanaging every case. Parties can still request reviews, but now they’ll land directly with Squires’ team, potentially speeding resolutions while inviting appeals to the Federal Circuit on final calls.
Background underscores the stakes. The AIA birthed the PTAB to curb “patent troll” abuse, slashing litigation costs by 40% per a 2023 PwC study. Yet critics, including pharma giants like Pfizer, argue PTAB tilts anti-patent, with institution rates dipping to 55% in biotech sectors last year. Squires’ tenure begins amid a patent filing boom—over 700,000 applications in FY2024—fueled by AI and green tech surges. His confirmation, 52-48 along party lines, drew fire from Democrats over his client list, including Amazon and Google, raising monopoly concerns in AI patenting.
IP attorneys are buzzing with cautious optimism. “This recaptures the Director’s constitutional perch, but risks bottleneck if Squires’ docket overflows,” said Michelle Lee, ex-USPTO Director and now Fenwick & West partner. She predicts a 20% uptick in Director interventions initially, echoing Vidal’s 24 granted reviews from 369 requests as of August 2024. On the flip side, David Prouty of Sterne Kessler warns it could “politicize institutions,” urging transparency via the USPTO’s Director Review status webpage. Public reactions on LinkedIn and IPWatchdog forums split: innovators hail it as a check on “forum shopping,” while challengers fret delays, with one post quipping, “From board to boss—patent poker just got a new dealer.”
For U.S. readers, this hits home across fronts. Economically, a streamlined PTAB could save businesses $5 billion annually in dispute costs, per USPTO estimates, boosting R&D in hotspots like Silicon Valley where 30% of startups tangle in validity fights. It might ease inflation pressures by clarifying IP ownership in supply chains, from semiconductors to EVs, where unresolved patents have jacked up component prices 15% since 2023. Politically, it aligns with the Trump administration’s “pro-innovation” push, dovetailing with proposed AIA tweaks in Congress to curb abusive IPRs—potentially swaying midterms in patent-heavy districts like Texas and California.
Lifestyle ripples too: Stronger Director control could safeguard consumer tech patents, accelerating gadgets from smart homes to wearables, while curbing frivolous suits that delay market entry. Technologically, it spotlights AI inventions; Squires has vowed guidance on patentable subject matter, addressing 2025’s 50% spike in AI-related filings amid OpenAI v. USPTO buzz. Even sports feels it—NIL deals for college athletes now hinge on trademark protections, with PTAB reviews stalling endorsements worth millions.
User intent drives this reform: Patent holders seek predictability to invest boldly, challengers want fair shots at invalid weak claims. Managing the transition means vigilant USPTO tracking—Squires pledges quarterly updates and an advisory committee blending PTAB, policy, and counsel voices to avoid Arthrex pitfalls.
As Squires’ first big play, this PTAB power grab signals a USPTO wired for executive muscle, with institution stats and appeal volumes set to tell the tale.
In summary, John Squires’ reclamation of review reins from the PTAB fortifies Director oversight in AIA proceedings, aiming for equity amid surging IP battles. Looking ahead, expect refined guidelines by Q1 2026, stakeholder roundtables, and Federal Circuit tests—paving a clearer path for U.S. innovation, if execution matches ambition.
By Sam Michael
Follow and subscribe to us for push notifications on breaking IP news.
USPTO Director review, PTAB authority shift, patent inter partes review, post-grant review changes, AIA proceedings overhaul, John Squires USPTO, Arthrex Director Review, patent institution decisions, Federal Circuit PTAB appeals, IP litigation reform